These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 38981769)
1. Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess. MacFarlane J; Korbonits M Best Pract Res Clin Endocrinol Metab; 2024 Jul; 38(4):101910. PubMed ID: 38981769 [TBL] [Abstract][Full Text] [Related]
2. The place of pegvisomant in the management of acromegaly. Parkinson C; Trainer PJ Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281 [TBL] [Abstract][Full Text] [Related]
3. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168 [TBL] [Abstract][Full Text] [Related]
4. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Tritos NA; Biller BM Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335 [TBL] [Abstract][Full Text] [Related]
5. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. Parkinson C; Trainer PJ Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267 [TBL] [Abstract][Full Text] [Related]
6. Experience with pegvisomant in the treatment of acromegaly. Drake WM Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081 [TBL] [Abstract][Full Text] [Related]
7. Pegvisomant in the treatment of acromegaly. Parkinson C; Scarlett JA; Trainer PJ Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709 [TBL] [Abstract][Full Text] [Related]
8. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823 [TBL] [Abstract][Full Text] [Related]
9. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly]. Zgliczyński W; Zdunowski P Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736 [TBL] [Abstract][Full Text] [Related]
10. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Yamaguchi H; Shimatsu A; Okayama A; Sato T Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069 [TBL] [Abstract][Full Text] [Related]
12. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Paisley AN; Trainer P; Drake W Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735 [TBL] [Abstract][Full Text] [Related]
14. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843 [TBL] [Abstract][Full Text] [Related]
15. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant. Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186 [TBL] [Abstract][Full Text] [Related]
16. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. Ezzat S; Gaspo R; Serri O; Ur E; Chik CL Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832 [TBL] [Abstract][Full Text] [Related]
17. Clinical use of pegvisomant for the treatment of acromegaly. Drake WM; Trainer PJ Treat Endocrinol; 2003; 2(6):369-74. PubMed ID: 15981941 [TBL] [Abstract][Full Text] [Related]
18. Pegvisomant: an advance in clinical efficacy in acromegaly. Stewart PM Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298 [TBL] [Abstract][Full Text] [Related]